Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05896228
Title Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd)
Acronym Iber-KDd
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Carl Ola Landgren, MD, PhD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.